Curanex Pharmaceuticals Inc Operating Expenses
Curanex Pharmaceuticals Inc (CURX) reported Operating Expenses of $3.33 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2026-08-14
- Curanex Pharmaceuticals Inc operating expenses for the quarter ending 2026-06-30 was $3.33M, a 5667.73% increase year-over-year.
- Curanex Pharmaceuticals Inc operating expenses for the quarter ending 2026-03-31 was $3.18M, a 2215.98% increase year-over-year.
- Curanex Pharmaceuticals Inc operating expenses for the quarter ending 2025-12-31 was $3.09M, a 1998.61% increase year-over-year.
- Curanex Pharmaceuticals Inc operating expenses for the quarter ending 2025-09-30 was $951.33K, a 919.70% increase year-over-year.
- Curanex Pharmaceuticals Inc operating expenses for fiscal 2025 was $4.24M, a 1061.19% increase from fiscal 2024.
- Curanex Pharmaceuticals Inc operating expenses for fiscal 2024 was $365.06K.
| Period end | Operating Expenses 3 month | Operating Expenses 6 month | Operating Expenses 9 month | Operating Expenses 12 month |
|---|---|---|---|---|
| 2026-06-30 | $3.33M 10-Q · filed 2026-08-14 | $6.51M 10-Q · filed 2026-08-14 | $9.60M derived: sum of 3 quarters · filed 2026-08-14 | $10.55M derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | $3.18M 10-Q · filed 2026-05-14 | $6.28M derived: sum of 2 quarters · filed 2026-05-14 | $7.23M derived: sum of 3 quarters · filed 2026-05-14 | $7.28M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-12-31 | $3.09M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $4.04M derived: sum of 2 quarters · filed 2026-03-30 | $4.10M derived: sum of 3 quarters · filed 2026-08-14 | $4.24M 10-K · filed 2026-03-30 |
| 2025-09-30 | $951.33K 10-Q · filed 2025-11-17 | $1.01M derived: sum of 2 quarters · filed 2026-08-14 | $1.15M 10-Q · filed 2025-11-17 | $1.29M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-06-30 | $57.66K 10-Q · filed 2026-08-14 | $195.11K 10-Q · filed 2026-08-14 | $342.48K derived: sum of 3 quarters · filed 2026-08-14 | $435.77K derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-03-31 | $137.45K 10-Q · filed 2026-05-14 | $284.82K derived: sum of 2 quarters · filed 2026-05-14 | $378.11K derived: sum of 3 quarters · filed 2026-05-14 | $422.31K derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | $147.37K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $240.66K derived: sum of 2 quarters · filed 2026-03-30 | $284.86K derived: sum of 3 quarters · filed 2026-03-30 | $365.06K 10-K · filed 2026-03-30 |
| 2024-09-30 | $93.30K 10-Q · filed 2025-11-17 | $137.50K derived: sum of 2 quarters · filed 2025-11-17 | $217.70K 10-Q · filed 2025-11-17 | |
| 2024-06-30 | $44.20K 10-Q · filed 2025-09-09 | $124.40K 10-Q · filed 2025-09-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |